Anti-IDH1 (R132H) antibody, Mouse monoclonal

Anti-IDH1 (R132H) antibody, Mouse monoclonal (mouse IgG1 isotype) is derived from the hybridoma HMab1 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a peptide corresponding to mutation R132H of human IDH1. A member of isocitrate dehydrogenase (IDH) family, IDH1, is the human cytoplasmic NADP-specific enzyme. Its subcellular localization was shown to be in both peroxisomes and the cytoplasm.

peptide corresponding to mutation R132H of human IDH1.

Anti-IDH1 (R132H) antibody has been used:

• in immunoblotting
• in immunohistochemistry
• in western blotting
• in cell cycle analysis and apoptosis assays
• in chromatin immunoprecipitation (ChIP) assay
• in in vitro migration assay

Isocitrate dehydrogenase 1 (IDH1) catalyzes the oxidative decarboxylation of isocitrate into α α -KG) using NADP as co-substrate. Mutations in IDH1 are specific to Arg132 (R132) and endow them with the function of generating 2-hydroxyglutarate (2HG) instead of α-KG. This product alters gene transcription through effects on DNA and histone methylation. Several IDH1 mutations exist, including R132H, R132C, R132S, R132G and R132L. Each may result in different tumor type with varied malignant progression. The most frequent known mutation (>90%) is the alteration of arginine to histidine (R132H). Hence, antibodies that recognize the IDH1^R132H mutation can be useful for the diagnosis of mutation-bearing tumors like gliomas.

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.